Using actinomycete lysate for preparing external nail care products

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to using actynomycete lysate for preparing external nail care products. Using actynomycete lysate of the strains Actinomyces R/3.88, L/1.89 or a mixture thereof for preparing external nail care products. A method for improving the appearance of the nails.

EFFECT: using the described actynomycete lysate improves the health and appearance of the nails.

2 cl, 1 tbl, 2 ex

 

The invention relates to the use of a lysate of actinomycetes for the preparation of external funds the care of nails.

In the invention of the USSR # 81396, priority dated September 27, 1948, describes a method for lysates of actinomycetes and apply these lysates for the diagnosis and treatment of actinomycosis in humans, intravenous (intradermal and intramuscular).

In the invention of the USSR №1584952, priority dated July 7, 1988, describes a method for preparation of lysate actinomycetes (actinolite)optionally purified from the high molecular weight fractions with molm 15000-25000 D.

Manual for doctors Applying actinolite in clinical practice", Moscow 2005, describes the use of injectable dosage forms lysate actinomycetes (actinolite) for the treatment of boils, chronic pyoderma, trophic ulcers, and other chronic diseases.

Thus, lysates of actinomycetes was previously used only as part of injectable dosage forms and never used before in the composition of external cosmetic or hygiene products, skin care, hair care, and oral cavity of the person. The lysate of actinomycetes is a composition of hydrophilic substances dissolved in water, and some of these active components of the lysate has a high molecular weight (>1000 D). The skin and mucous membranes of a person before whom represent an effective barrier to the transport of hydrophilic substances and especially substances with high molecular weight, therefore, the components of the lysate actinomycetes are not absorbed by the skin or mucous in therapeutically effective concentrations, and the lysate actinomycetes generally ineffective as a medicine for external application.

However, we have found that lysates of actinomycetes, especially of the genus Actinomyces, effective when external and local application as part of nail care. Application of these lysates improves the appearance of the nails of a person that was not previously known from the prior art. The lysate actinomycetes improves the metabolism of the skin cells of the skin, especially under the action of Pro-inflammatory factors that determines its effectiveness in the outer and/or local application as part of nail care.

The present invention is the use of a lysate of actinomycetes for making exterior cosmetic and/or hygienic care for nails.

The essence of the invention lies in the fact that for the preparation of external funds the care of nails is used, the lysate of actinomycetes.

The term "lysate" means a sterile filtrate of the culture fluid obtained after lysis of actinomycetes, pre-grown in culture conditions. The lysate actinomycetes of the genera Actinomyces prepared by methods well what about the known from the prior art. For example, these actinobacteria are cultivated within 1.5-2 months at 37°C, after which spontaneously lyse the culture fluid is filtered, and the product emit drying the obtained sterile filtrate.

The term "nail care" means measures aimed respectively at improving the health and appearance of the nails.

Preferably, for the preparation of the means of the present invention is applied lysate actinomycetes of the genera Actinomyces. More preferably, the lysate is applied actinomycetes strains of Actinomyces R/3.88, L/1.89, or their mixture.

Preferably, an effective amount of a lysate of actinomycetes in the means of care of skin, hair, nails, oral cavity of the present invention is 0.0001-10.00 wt.%. More preferably, 0.01 to 0.05 wt.%.

The tool according to the present invention can be manufactured as a cosmetic, hygienic or antiseptic agent in various forms, for example, in the form of solutions, lotions, spree, gels, suspensions, emulsions, ointments, creams, and beauty balms. The tool can also be in the form of microspheres, nanospheres, lipid or polymeric vesicles or polymeric patches and hydrogels allowing controlled release of the active components of the lysate.

The tool according to the present invention MoE is et to be applied to improve the appearance and health of nails in humans, suffering from brittle nails, splitting nails, thinning of the edge of the nail and the slow growth of the nail. According to the present invention, a tool for nail care can be used to care for the nails of the hands and nails of the feet.

According to the present invention, a tool for nail care, containing lysate of actinomycetes, is applied to the nails and skin around the nails of a human, in need thereof.

Means for care of nails according to the present invention may contain additional components, for example, amino acids, vitamins and minerals. Examples of amino acids include, but are not limited to, glycine, Proline, leucine, valine, methionine, cysteine, tyrosine, and arginine. Examples of minerals include, but are not limited to, salts of calcium, magnesium, and zinc. Examples of vitamins include, but are not limited to, vitamins B1, B2, B3, B6, B12, choline, ascorbic acid, and vitamin D. Preferably, the content of the additional components in the tool according to the present invention is 0.0001-to 35.0 wt.%, more preferably 0.1 to 10.0 wt.%

Means for care of nails according to the present invention may further comprise excipients, for example, amplifiers absorption (organic acids and surfactants), geleobrazovanie, ant the oxidants, preservatives, buffers, colorants and odorants in the amount necessary to make the tool stability and acceptable performance characteristics. Auxiliary substances may be contained in the composition in an amount of 0.01÷25.00 wt.%. Examples of geleobrazovanie include, but are not limited to, cellulose derivatives (karboksimetilcelljuloza) and derivatives of polyacrylic acid. Examples of antioxidants include, but are not limited to, ascorbic acid and its salts. Examples of preservatives include, but are not limited to, EDTA and benzalkonium salts. Examples of buffers include, but are not limited to, citrate buffer, phosphate buffer, oxalate buffer, acetate buffer, ensuring acceptable pH means, preferably a pH of 4.2÷7,0, more preferably a pH of 5.5.

The tool nail care according to the present invention are made by methods well known in the prior art. For example, a lysate of actinomycetes of the genera Actinomyces and auxiliary components are mixed in the mixer in the above proportions. The resulting product is packaged in containers designed for individual use. Examples of such containers include bottles, vials, jars, tubes, etc.

The following examples illustrate the invention. Examples are presented for illustration only, and neither will the way do not limit the scope of the invention.

Example 1

Table 1 demonstrates the use of a lysate of actinomycetes for making preparations for the care of nails, made in the form of a gel.

Table 1
CompositionContent, wt.%
The lysate actinomyces Actinomyces R/3.88, L/1/895
Citric acid1,0
Sodium hydroxide1,00
Karboksimetilcelljuloza2
Benzalconi chloride0,2
EDTA0,1
Distilled waterRest

The gel is prepared as follows. The lysate actinomycetes, citric acid, karboksimetilcelljuloza, sodium hydroxide, benzalconi chloride, EDTA made in water and mixed until the formation of gel with a pH of 5.5. The resulting product is placed in the tubes.

Example 2

Three women 37, 45, and 46 years with chronic delamination and brittle nails inflicted tool for nail care composition, according to stoysin table 1 example 1 a day for four weeks on the nail plate and the skin around the nail plate fingers. After completing the course of treatment, nails are much stronger and ceased to delaminate. The average speed of the nails increased from 2.0 ą 0.3 to 3.2±0.4 mm/month. Thus, the use of funds to care for the nails of the present invention significantly improves the health and appearance of the nails.

1. The use of a lysate of actinomycetes strains of Actinomyces P/3.88, L/1.89 or mixtures thereof for the preparation of external funds for the care of nails.

2. The way to improve the appearance of nails, characterized in that the lysate of actinomycetes according to claim 1 is applied to the nail plate.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacological and cosmetic industry, namely to a dermatological agent. The dermatological agent containing antler deer's dry blood plasma, Mumiyo, D-Panthenol, Sea buckthorn oil and additives in certain proportions.

EFFECT: above dermatological agent possesses higher bioavailability and biological activity, as well as extends the range of similar products.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine. An antimicrobial composition contains chlorhexidine and pentane-1,5-diol, wherein the amount of chlorhexidine makes 0.000001 to 5 wt %, while the amount of pentane-1,5-diol makes 1 to 75 wt %. The composition is applicable for local administration; it contains a carrier and a gelling material.

EFFECT: group of inventions enables applying the composition for non-therapeutic disinfection, in treating skin infections.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to dentistry and may be used for making hygienic and therapeutic products for daily dental and oral care, namely to mouth rinses. A mouth rinse formulation contains troxerutin 0.1-0.3 wt % in a combination with ectoin 0.01-1.0 wt %, nicotinamide 0.05-0.1 wt % and a complex of bisabolol and ginger extract 0.01-0.03 wt %, as well as a cosmetically acceptable base containing a water-retaining additive, a structure-forming agent, a filming agent, an anti-caries additive, a flavouring agent and a target additive in the amounts to provide performing the above functions, a biologically active additive consisting of Aloe Vera and herbal infusion, while a medium is water.

EFFECT: formulation provides the effective repair action on the periodontal tissues and high cleansing properties when using the mouth rinse.

14 cl, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and represents a sun-protection cream consisting of aqueous-alcohol extract of grape skins, CO2-extract of grape skins, olive oil, isopropyl myristate, higher synthetic primary fatty alcohols C16-C20 fraction, polyethylene glycol-400 stearate, bee wax, glycerol, stearine, triethanolamine, benzyl alcohol, a preserving agent, a flavouring agent and water with the ingredients of the cream are found in certain proportions, wt %.

EFFECT: invention provides a higher rate of sun-protective action of the sun-protection cream.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetic industry and represents an oil-in-water emulsion composition for UV protection, containing: (a) octocrylene, (b) bis- ethylhexyloxyphenol methoxyphenyl triazine, (c) hexyldiethylamino-hydroxybenzoyl benzoate, (d) 4-tert-butyl-4'-methoxybenzoyl methane, wherein the amount of the ingredients (a), (b), (c) and (d) makes 1 - 40 wt/wt %, (e) a water-soluble polymer in the amount of 0.01-5 wt/wt %, (f) a water-swellable clay mineral in the amount of 0.01-4 wt/wt %, (g) an oil ingredient having NOB 0.05 or more in the amount of 1 - 70 wt/wt %, (h) a higher fatty acid in the amount of 0.1-10 wt/wt %, (i) a surfactant in the amount of 0.1-10 wt/wt %, (j) water - the rest, wherein all the amounts are presented as a percentage of the total amount in the oil-in-water emulsion composition.

EFFECT: invention provides developing the composition having the good UV protection effect, exhibiting the emulsion stability and pleasant sensation.

6 cl, 8 ex, 4 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to cosmetology and represents a cosmetic product for face and body skin care containing a basic component presented by dry feed rye spent wash with syrup, as well as at least one paste-forming component specified in a group: water, liquid soap and optionally at least one component specified in a group of: sugar-free cultured milk product, rye flour, vegetable oil, honey.

EFFECT: invention provides preparing the high efficacy natural dry cosmetic product for face, hand and body skin cleansing, nourishment and regulation.

7 cl, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claim describes a cosmetic or dermatological composition in the form of cream, foam, spray, gel, gel spray, lotion, oil, oil gel or mousse. The composition contains at least one active substance, at least one molecular imprinted polymer in the presence of the same active substance, and at least one oil phase. The polymer contains a) a monoethylene-saturated mono- or dicarboxylic acid or α,β-ethylene-unsaturated mono- or dicarboxylic acid esters with diols and b) methacrylic acid esters of at least dihydric alcohols. The molar ratio of the compounds a) and b) makes 1:2 to 1:4, and the polymer is prepared in the medium of a solvent wherein monomers, but not the polymer to be prepared is dissolved in the presence of the active substance.

EFFECT: combination of the molecular imprinted polymer prepared by precipitative polymerization, and the oil phase provides the release of the active substance both in the water phase, and in the oil phase which ensures the best contact with a lipophilic surface, such as skin.

3 cl, 3 dwg, 7 tbl, 37 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a polyphenol derivative formulation and is used in cosmetics, nutrition science and therapy. The polyphenol derivative formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress. A method for preparing the formulation. The cosmetic formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress. Using the formulation in nutrition science. The formulation to be used as a therapeutic agent possessing antioxidant and antiradical activity and having an effect on carbonyl stress. The pharmaceutical formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress.

EFFECT: formulation has an effect on carbonyl stress.

23 cl, 11 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and represents an oil-in-water emulsion sun-protection cosmetic composition containing: (A) 1 to 7.5 wt % of octyl methoxycinnamate; (B) 1 to 4 wt % of tret-butyl methoxydibenzoyl methane and/or 2-hydroxy-4-methoxybenzophenone; (C) 0.5 to 3 wt % of a polyoxyethylene/polyoxyalkylene alkyl ester block copolymer; (D) 10 wt % or more of a nonpolar oil relative to the total amount of the oil component; wherein an average emulsion particle diameter makes not more than 700 nm.

EFFECT: invention provides developing the stable sun-protection composition having improved ultraviolet blocking capability and good usability.

4 ex, 4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to cosmetology, particularly a composition enriched with silver nanoparticles and a method of producing said composition. The composition is intended to replace water as the basic component for producing cosmetic products (shampoos, Balsams, masks, intimate hygiene agents, creams etc). The composition contains a dry 65% whey protein concentrate, a micellar solution of silver nanoparticles in form of an aqueous solution having concentration of 500 mg/l in amount of 0.01-0.5% and additionally water. The method of producing said composition involves heating water to temperature of 50-55°C, adding the whey protein concentrate to the heated water in portions, recirculating the obtained mixture for 15 minutes using a cam-driven pump, adding the micellar solution of silver nanoparticles to the stirred mixture and cooling the obtained mixture to 30°C.

EFFECT: invention enables to obtain cosmetic material which protects skin from inflammatory processes and ageing, controls and maintains the skin water-oil balance.

2 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely to the application of a probiotic of the species Lactobacillus rhamnosus in preparing a composition for normalising a patient's pathological lipid profile, wherein the above profile comprises lysophospholipid and/or ceramide sphingolipid. A method for normalising the patient's pathological lipid profile by administering the probiotic of the species Lactobacillus rhamnosus in an amount sufficient to achieve the desired effect, into the patient.

EFFECT: using the probiotic of the species Lactobacillus rhamnosus as a part of the composition enables normalising the patient's pathological lipid profile comprising lysophospholipid and/or ceramide sphingolipid.

12 cl, 2 tbl, 4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method for preparing a bacterial preparation for preventing bovine postpartum endometritis consisting in the fact that preparing involves making a dry nutrient broth for microorganism culture (DNB) according to the package insert; the prepared broth is added with 3% starch pre-dissolved in a small amount of the cooled broth, and then mixed with the rest DNB; the broth is brought to the boiling point, boiled to produce a homogenous transparent mass; then the medium is added with 0.125% NaCl and 2% glucose to pH 6-7, then a phosphate buffer is added: one-substituted 0.8% potassium KH2PO4 and 0.18% two-substituted potassium or sodium K2HPO4 or Na2HPO4; the solution is boiled for 15 minutes, and after cooling, it is added with 0.5% of 80% lactic acid, filtered and autoclaved at 0.5 atm. for 30-40 min; after the solution has been cooled, it is added with the prepared cultures of Lactobacillus fermentum 44/1 and Lactococcus lactis subsp.Lactis 574 no 1 bln. of the microbial cells per 100 ml of the medium in the sterile environment; it is packaged and thermostated for 48 hours at t=37°C. The preparation is tested in 56 cows for the purpose of preventing bovine postpartum endometritis.

EFFECT: invention provides reducing the cost price of the preparation as compared to its prototype by 60%, without impairing the prophylactic efficacy, eliminates using antibiotics and derivatives thereof, sulphanyl amides, nitrofuranes and thereby eliminates side action of the preparation on animal's body.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, and may be used for treating the patients with chronic non-specific endometritis. The method is implemented as follows: a therapeutic agent that is polyvalent complex pyobacteriophage in a dose of 4-7 ml is introduced in a female patient with a completely empty bladder on the 5-7th postmenstrual day. There are 5 procedures of administering pyobacteriophage required. That is followed by the exposure to low-intensity infrared pulse laser at wave length 0.89 mcm, frequency 80 Hz, pulse power 5 Wt; the cutaneous daily 10-minute exposure covers the underbelly. For the 5 of 10 minutes, the exposure covers a projection of the uterus, while for the rest 5 minutes, a projection of the annexes are exposed. The therapeutic course is 10 procedures. Besides, the underbelly exposure is combined with the daily exposure covering a projection of the cubital vessels and the suprasternal notch for 2-3 minutes with the therapeutic course making 10 procedures. The exposure on a projection of the cubital vessels and the suprasternal notch may be both combined with the underbelly exposure, and follow the same.

EFFECT: method provides the clinical effectiveness and provides ensures reducing the clinical manifestations of the disease, improving the ultrasound, doppler and laboratory parameters, normalising the genital micro-biocoenosis, optimising the female reproductive functions in a combination with a low rate of potential systemic side effects.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynecology, endocrinology and can be used for correction of vaginal dysbiosis in case of metabolic syndrome. For this purpose complex impact on the organism by correction of body weight by means of no-pharmaceutical and pharmaceutical preparations is performed. Hypocaloric diet with reduced caloric content of 500-600 kcall/day, with reduced content of fats in food up to 20-30% and hypolipidemic direction is administered. Increased physical activity and xenical preparation are also administered for 6 months. Correction of metabolic disorders is carried out by means of preparations possessing antioxidant and membrane-stabilising action daily for 3 months. Recovery of vaginal microflora is performed by means of preliminary sanitation of vaginal biotope with antibacterial preparations for 7 days and immunocorrection for 10 days with further administration of eubiotic preparations for 5-7 days. Correction of vaginal dysbiosis is carried out until amount of opportunistic bacteria decreases and/or content of normal microflora is recovered.

EFFECT: method ensures increased efficiency of correction of dysbiotic vaginal disturbances in case of metabolic syndrome.

1 ex, 1 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and is intended to prevent the age-related changes of hepatic tissue in rats experimentally. What is used is the biologically active additive "Rekicen RD" added to the diet of inbred laboratory rats at the age of two years old. A dose is 2 grams a day for 14 days.

EFFECT: method enables improving the hepatic tissue state ensured by increasing the regeneration activity of hepatocytes.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be applied in treating secondary lactase deficiency. For this purpose, with underlying diet and drug-induced therapy, bifiform 1 tablet 2-3 times a day and No-spa 1-2 tablets 3 times a day are additionally administered. The therapeutic course makes 14 days.

EFFECT: method enables higher clinical effectiveness in secondary lactase deficiency.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day.

EFFECT: method ensures increased efficiency of treatment of non-alcoholic fatty liver disease with reduction of side effects.

6 ex, 12 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and biotechnology and represents a therapeutic antimalaria drug containing an antimalaria agent and excipients differing by the fact that it additionally contains a biomass of the Bacillus subtilis probiotic strains in the amount of CFU not less than 1×108 cell/tablet (dose) with the ingredients in the preparation taken in certain proportion, wt %.

EFFECT: invention provides antiprotozoal action with probiotic effect.

7 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial strains Escherichia coli wherein the process of preparing the extract involves lysing one or more bacterial strains at pH more than 12 and processing the extract to separate nucleic acids, and wherein the extract: causes no risk of a prion disease when introduced into the patient, contains less than 100 mcg/ml of nucleic acid, contains chemically modified saccharides, including chemically modified lipopolysaccharide, and contains at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine; and it is racemised at least by 10%.

EFFECT: invention provides maximum safety and efficacy.

52 cl, 9 ex, 6 tbl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial species specified in Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus sanguinis, wherein while preparing said extract one or more bacterial strains are lysed at pH more than 12, and the extract is processed in order to remove nucleic acids; and wherein the extract dies not cause the onset of a prion disease if introduced into a patient wherein the extract contains less than 100 mcg/ml of nucleic acid, wherein the extract contains chemically modified saccharide, including chemically modified lipopolysaccharide, and wherein at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine, is racemised at least by 10%.

EFFECT: invention does not cause a risk or eliminates a risk of the prion disease when introduced into the patient that provides maximum safety and efficacy.

48 cl, 12 ex, 10 dwg

FIELD: veterinary science.

SUBSTANCE: it is suggested to apply sulfatetrine M and probiotic ocarine for calves by the following dosage-temporal scheme: sulfatetrine M at the dosage of 0.2-0.4 g/kg body weight starting since the second colostral feeding, and then at a 12-h-long interval for 7 d; ocarine - at the dosage of 8x106 microbial cells once daily for nocturnal period for 10 d. The suggested combination enables to considerably decrease side effects, provides immunocorrection of the main affected immunity links, for example, prophylactic efficiency of the method corresponds to above 90% at 100% safety of calves.

EFFECT: higher natural body resistance.

2 ex, 4 tbl

Up!